Boston Scientific to Report Q4 Earnings with Expected Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy BSX?
Source: Benzinga
- Earnings Release Announcement: Boston Scientific is set to release its fourth-quarter earnings on February 4 before the market opens, with analysts projecting earnings of 78 cents per share, an increase from 70 cents in the same period last year, indicating ongoing improvement in profitability.
- Revenue Growth Expectations: Analysts anticipate the company will report quarterly revenue of $5.28 billion, up from $4.56 billion last year, reflecting strong performance and increased demand in the medical device market.
- FDA Warning Impact: The U.S. Food and Drug Administration (FDA) indicated last month that Boston Scientific has alerted customers to cease the use of certain AXIOS stents and electrocautery-enhanced delivery systems due to high patient risk during procedures, which could negatively affect the company's reputation and sales.
- Stock Price Fluctuation: Boston Scientific's shares fell 0.3% to close at $91.62 on Tuesday, and while the earnings report is forthcoming, the market's reaction to the FDA warning may impact investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BSX is 125.74 USD with a low forecast of 112.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 91.870
Low
112.00
Averages
125.74
High
140.00
Current: 91.870
Low
112.00
Averages
125.74
High
140.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific to Report Q4 Earnings with Expected Growth
- Earnings Release Announcement: Boston Scientific is set to release its fourth-quarter earnings on February 4 before the market opens, with analysts projecting earnings of 78 cents per share, an increase from 70 cents in the same period last year, indicating ongoing improvement in profitability.
- Revenue Growth Expectations: Analysts anticipate the company will report quarterly revenue of $5.28 billion, up from $4.56 billion last year, reflecting strong performance and increased demand in the medical device market.
- FDA Warning Impact: The U.S. Food and Drug Administration (FDA) indicated last month that Boston Scientific has alerted customers to cease the use of certain AXIOS stents and electrocautery-enhanced delivery systems due to high patient risk during procedures, which could negatively affect the company's reputation and sales.
- Stock Price Fluctuation: Boston Scientific's shares fell 0.3% to close at $91.62 on Tuesday, and while the earnings report is forthcoming, the market's reaction to the FDA warning may impact investor confidence.
See More
Boston Scientific Set to Announce Q4 Earnings on February 4
- Earnings Announcement: Boston Scientific (BSX) is set to release its Q4 2023 earnings on February 4 before the market opens, with consensus EPS estimates at $0.78, reflecting an 11.4% year-over-year increase, and revenue estimates at $5.28 billion, indicating a 15.8% year-over-year growth, showcasing the company's robust growth potential.
- Consistent Outperformance: Over the past two years, BSX has consistently beaten both EPS and revenue estimates 100% of the time, underscoring the company's financial stability and market confidence, which further enhances investor optimism regarding its future performance.
- Estimates Revision Trend: In the last three months, BSX's EPS estimates have seen two upward revisions with no downward adjustments, while revenue estimates have experienced seven upward revisions and one downward, reflecting an increasing confidence among analysts regarding the company's future performance.
- Increased Market Attention: With BSX's ongoing investments and innovations in the neurovascular sector, market attention towards its future growth engines is rising, particularly in its collaboration with Penumbra, highlighting the company's strategic positioning and competitive advantages in the medical device industry.
See More
Analysis and Outlook: A New Decline in Software Performance
Market Trends: The software market is experiencing a significant selloff, indicating a downturn in investor confidence.
Company Focus: Anthropic, a key player in the AI sector, is highlighted amidst the broader market challenges.
See More
Investigation Alerts for Multiple Company Mergers
- RAPT Acquisition Investigation: RAPT Therapeutics is set to be acquired by GlaxoSmithKline for $58 per share, totaling an estimated equity value of $2.2 billion, with investigations focusing on whether the board failed to conduct a fair process, potentially impacting shareholder rights.
- Calavo Merger Details: Calavo Growers will be acquired by Mission Produce, with shareholders receiving $27 per share, including $14.85 in cash and 0.9790 shares of Mission, valuing the transaction at approximately $430 million, while investigations examine if the board breached fiduciary duties to shareholders.
- Penumbra Acquisition Status: Penumbra will be acquired by Boston Scientific in a deal valuing the company at $374 per share, reflecting an enterprise value of about $14.5 billion, with investigations looking into whether the board ensured a fair process, potentially affecting shareholder interests.
- FONAR Merger Investigation: FONAR Corporation is to be acquired by FONAR, LLC for $19 per share in an all-cash transaction, with investigations questioning whether the board failed to conduct a fair process, which could impact shareholder rights.
See More
Acquisition Investigations Reminder for Multiple Companies
- RAPT Acquisition Investigation: RAPT Therapeutics is set to be acquired by GlaxoSmithKline for $58 per share, representing an estimated total equity value of $2.2 billion, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process.
- Calavo Transaction Details: Calavo Growers will be acquired by Mission Produce for $27 per share, consisting of $14.85 in cash and 0.9790 shares of Mission, valuing the enterprise at approximately $430 million, with investigations into the board's adherence to fair transaction practices.
- Penumbra Acquisition Status: Penumbra will be acquired by Boston Scientific at $374 per share, reflecting an enterprise value of around $14.5 billion, with investigations examining whether the board ensured fair value for shareholders in the deal.
- FONAR Acquisition Investigation: FONAR Corporation is set to be acquired for $19 per share in an all-cash transaction, with investigations looking into whether the board fulfilled its fiduciary duties to shareholders by ensuring the fairness of the transaction.
See More
Super Bowl of Earnings for S&P 500
- Disney Earnings Highlights: Disney reported Q1 EPS of $1.63, surpassing the $1.57 estimate, with revenue of $25.98 billion exceeding expectations of $25.74 billion, indicating strong performance in the entertainment sector, although CEO Bob Iger plans to step back from daily management before his contract ends.
- Palantir Earnings Focus: Palantir is set to report earnings after Monday's close, with investors closely monitoring its commercial customer count and average revenue per customer, as these metrics reflect the adoption of its AI platforms beyond government contracts, impacting its high valuation sustainability.
- AMD Earnings Expectations: Analysts expect AMD to report earnings of $1.32 per share on revenue of $9.67 billion, with the market anticipating a beat-and-raise quarter driven by growth in MI350 AI accelerators and server CPU market share gains, potentially pushing the stock to new all-time highs.
- Google Cloud Competitiveness: Investors will keep an eye on Google Cloud's momentum and the successful monetization of Gemini AI within search and YouTube to ensure the company maintains its competitive edge against AI rivals, especially in light of its massive capital expenditure plans for AI infrastructure.
See More
Boston Scientific to Report Q4 Earnings with Expected Growth
- Earnings Release Announcement: Boston Scientific is set to release its fourth-quarter earnings on February 4 before the market opens, with analysts projecting earnings of 78 cents per share, an increase from 70 cents in the same period last year, indicating ongoing improvement in profitability.
- Revenue Growth Expectations: Analysts anticipate the company will report quarterly revenue of $5.28 billion, up from $4.56 billion last year, reflecting strong performance and increased demand in the medical device market.
- FDA Warning Impact: The U.S. Food and Drug Administration (FDA) indicated last month that Boston Scientific has alerted customers to cease the use of certain AXIOS stents and electrocautery-enhanced delivery systems due to high patient risk during procedures, which could negatively affect the company's reputation and sales.
- Stock Price Fluctuation: Boston Scientific's shares fell 0.3% to close at $91.62 on Tuesday, and while the earnings report is forthcoming, the market's reaction to the FDA warning may impact investor confidence.
See More
Boston Scientific Set to Announce Q4 Earnings on February 4
- Earnings Announcement: Boston Scientific (BSX) is set to release its Q4 2023 earnings on February 4 before the market opens, with consensus EPS estimates at $0.78, reflecting an 11.4% year-over-year increase, and revenue estimates at $5.28 billion, indicating a 15.8% year-over-year growth, showcasing the company's robust growth potential.
- Consistent Outperformance: Over the past two years, BSX has consistently beaten both EPS and revenue estimates 100% of the time, underscoring the company's financial stability and market confidence, which further enhances investor optimism regarding its future performance.
- Estimates Revision Trend: In the last three months, BSX's EPS estimates have seen two upward revisions with no downward adjustments, while revenue estimates have experienced seven upward revisions and one downward, reflecting an increasing confidence among analysts regarding the company's future performance.
- Increased Market Attention: With BSX's ongoing investments and innovations in the neurovascular sector, market attention towards its future growth engines is rising, particularly in its collaboration with Penumbra, highlighting the company's strategic positioning and competitive advantages in the medical device industry.
See More
Analysis and Outlook: A New Decline in Software Performance
Market Trends: The software market is experiencing a significant selloff, indicating a downturn in investor confidence.
Company Focus: Anthropic, a key player in the AI sector, is highlighted amidst the broader market challenges.
See More
Investigation Alerts for Multiple Company Mergers
- RAPT Acquisition Investigation: RAPT Therapeutics is set to be acquired by GlaxoSmithKline for $58 per share, totaling an estimated equity value of $2.2 billion, with investigations focusing on whether the board failed to conduct a fair process, potentially impacting shareholder rights.
- Calavo Merger Details: Calavo Growers will be acquired by Mission Produce, with shareholders receiving $27 per share, including $14.85 in cash and 0.9790 shares of Mission, valuing the transaction at approximately $430 million, while investigations examine if the board breached fiduciary duties to shareholders.
- Penumbra Acquisition Status: Penumbra will be acquired by Boston Scientific in a deal valuing the company at $374 per share, reflecting an enterprise value of about $14.5 billion, with investigations looking into whether the board ensured a fair process, potentially affecting shareholder interests.
- FONAR Merger Investigation: FONAR Corporation is to be acquired by FONAR, LLC for $19 per share in an all-cash transaction, with investigations questioning whether the board failed to conduct a fair process, which could impact shareholder rights.
See More
Acquisition Investigations Reminder for Multiple Companies
- RAPT Acquisition Investigation: RAPT Therapeutics is set to be acquired by GlaxoSmithKline for $58 per share, representing an estimated total equity value of $2.2 billion, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process.
- Calavo Transaction Details: Calavo Growers will be acquired by Mission Produce for $27 per share, consisting of $14.85 in cash and 0.9790 shares of Mission, valuing the enterprise at approximately $430 million, with investigations into the board's adherence to fair transaction practices.
- Penumbra Acquisition Status: Penumbra will be acquired by Boston Scientific at $374 per share, reflecting an enterprise value of around $14.5 billion, with investigations examining whether the board ensured fair value for shareholders in the deal.
- FONAR Acquisition Investigation: FONAR Corporation is set to be acquired for $19 per share in an all-cash transaction, with investigations looking into whether the board fulfilled its fiduciary duties to shareholders by ensuring the fairness of the transaction.
See More
Super Bowl of Earnings for S&P 500
- Disney Earnings Highlights: Disney reported Q1 EPS of $1.63, surpassing the $1.57 estimate, with revenue of $25.98 billion exceeding expectations of $25.74 billion, indicating strong performance in the entertainment sector, although CEO Bob Iger plans to step back from daily management before his contract ends.
- Palantir Earnings Focus: Palantir is set to report earnings after Monday's close, with investors closely monitoring its commercial customer count and average revenue per customer, as these metrics reflect the adoption of its AI platforms beyond government contracts, impacting its high valuation sustainability.
- AMD Earnings Expectations: Analysts expect AMD to report earnings of $1.32 per share on revenue of $9.67 billion, with the market anticipating a beat-and-raise quarter driven by growth in MI350 AI accelerators and server CPU market share gains, potentially pushing the stock to new all-time highs.
- Google Cloud Competitiveness: Investors will keep an eye on Google Cloud's momentum and the successful monetization of Gemini AI within search and YouTube to ensure the company maintains its competitive edge against AI rivals, especially in light of its massive capital expenditure plans for AI infrastructure.
See More
